&w=3840&q=100)
Concord Biotech rises 2% on incorporating its arm for marketing and sales
The market capitalisation of the company stood at ₹20,190.93 crore. The 52-week high of the company stood at ₹2,658 per share, and the 52-week low was at ₹1,370.05.
Why were Concord Biotech shares buzzing in trade?
The buying on the counter came after the company incorporated its subsidiary Concord Lifegen, with an objective to carry out marketing, sales, and distribution of pharmaceutical products. The total cost of acquisition is worth ₹1,00,000.
"We are pleased to announce incorporation of Concord's Wholly Owned subsidiary company, namely, 'Concord Lifegen Limited' with objective to carry out marketing, sales, and distribution of pharmaceutical products," the filing read.
Its primary objectives include executing targeted sales strategies, ensuring regulatory compliance across domestic and international markets, handling logistics and customer support, and maintaining transparent reporting to the holding company, according to the filing.
The authorised share capital (as on July 22, 2025) of Concord Lifegen is ₹1,00,000 divided into 10,000 equity shares of ₹10 each issued share capital (as on July 22, 2025).
That apart, in Q4, the company's profit climbed 47.8 per cent year-on-year (Y-o-Y) to ₹140 crore in the March quarter of FY25, from ₹95 crore in the March quarter of FY24. Concord Biotech's revenue from operations surged 34.8 per cent Y-o-Y to ₹429.9 crore in Q4FY25, from ₹319 crore in the same quarter a year ago.
About Concord Biotech
Concord Biotech is a research-driven biopharmaceutical company specialising in the production of Active Pharmaceutical Ingredients (APIs) through fermentation and semi-synthetic processes, along with finished formulations.
Initially a single-product entity, Concord has evolved into a comprehensive solutions provider, offering a broad range of products across various therapeutic segments. The company has established a global presence, distributing its products in over 70 countries, including key markets like the USA, Europe, Japan, and Latin America, while also maintaining a major footprint in India.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fibre2Fashion
23 minutes ago
- Fibre2Fashion
Godavari Biorefineries gets Chinese patent for cancer molecule
Godavari Biorefineries Limited (BSE: 544279 | NSE: GODAVARIB), through its clinical-stage biotech division Sathgen Therapeutics, has been granted a patent by the China National Intellectual Property Administration (CNIPA), China's patent and trademark office for its novel anti-cancer molecule - HYDROXY-1,4-NAPHTHALENEDIONE. This patent covers a novel class of compounds that have exhibited strong inhibitory effects on cancer and cancer stem cells in vitro studies. These compounds have demonstrated significant efficacy against multiple cancer cell types, including breast and prostate cancer. 'Our focus on original, high-quality science continues to guide our journey beyond green chemistry into life sciences,' said Dr Sangeeta Srivastava, Executive Director, Godavari Biorefineries Limited. 'This Chinese patent reinforces the promise of our lead molecule and the vital work being done by our team at Sathgen Therapeutics to develop innovative therapies for some of the most pressing medical needs worldwide.' Godavari Biorefineries has established a global presence, exporting to over 20 countries and maintaining strong linkages with international research and development networks. The company's clinical-stage biotech division, Sathgen Therapeutics, is at the forefront of advancing novel cancer and antiviral therapies. With a lead molecule undergoing clinical trials and global patent protection, GBL is deepening its focus in translational research that addresses some of the world's most urgent health challenges. Note: The headline, insights, and image of this press release may have been refined by the Fibre2Fashion staff; the rest of the content remains unchanged. Godavari Biorefineries' biotech arm, Sathgen Therapeutics, has secured a Chinese patent for its anti-cancer molecule Hydroxy-1,4-Naphthalenedione. The compound shows strong in vitro efficacy against cancer and cancer stem cells. GBL continues to expand globally, focusing on innovative cancer and antiviral therapies through advanced translational research. ALCHEMPro News Desk (HU)
Mint
an hour ago
- Mint
Natco Pharma shares to be in focus on Thursday after ₹2,000 crore acquisition move. Details here
Pharmaceutical firm Natco Pharma's share price will be in focus of stock market investors on Thursday, 24 July 2025, after the company's board of directors approved the ₹ 2,000 crore acquisition move of a South African firm, according to an exchange filing. Natco Pharma will acquire over 5.16 crore shares of Adcock Ingram Holdings Ltd, South Africa, for a total investment cost of ₹ 2,000 crore, including the transaction cost and other expenses. 'To acquire 51,643,319 Shares (5,03,51,444 Ordinary Shares from public and 12,91,875 Treasury Shares/Fresh Issuance from Adcock Ingram Holdings Limited) at a cash offer of ZAR 75.00 (approximately US$ 4.27) per share, i.e., 35.75% (inclusive of prior to acquisition shareholding of 0.80%) of shares of the Adcock Ingram Holdings Ltd, South Africa, with a total investment cost of approx. ₹ 2000,00,00,000/- (Rupees Two Thousand Crores only) including the transaction cost and other expenses,' the company informed BSE through the filing. The company will also incorporate NATCO Pharma South Africa Proprietary Limited, with an investment of up to ₹ 2,100 crore. Natco Pharma share price closed 2.01% higher at ₹ 1,034.75 after Wednesday's stock market session, compared to ₹ 1,014.35 at the previous market close. The company announced the acquisition update after the market operating hours on 23 July 2025. The pharmaceutical company's shares have given stock market investors more than 41% returns in the last five years. However, the stock has lost 17.92% in the last one-year period. On a year-to-date (YTD) basis, the shares are down 26% in 2025, but are trading 18.96% higher in the last one-month period. Natco Pharma shares hit their 52-week high level at ₹ 1,638.35 on 12 September 2025, while the 52-week low level was at ₹ 660.05 on 7 April 2025, according to BSE data. The company's market capitalisation (M-Cap) stood at ₹ 18,533.39 crore as of the stock market close on Wednesday, 23 July 2025. Read all stories by Anubhav Mukherjee Disclaimer: This story is for educational purposes only. The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
&w=3840&q=100)
Business Standard
an hour ago
- Business Standard
Syngene Q1 PAT up 59% to ₹87 crore, operational revenue rises 11%
Biocon arm Syngene International's consolidated net profit rose to Rs 87 crore, up 59 per cent year-on-year (Y-o-Y) in the first quarter of the financial year 2026 (Q1 FY26) ended June 30, according to a company statement. Revenue from operations grew 11 per cent Y-o-Y to Rs 875 crore. The performance was driven by continued conversion of pilot programmes into long-term contracts within the Research Services business. The Q1 FY25 profit after tax (PAT) excludes an exceptional item of Rs 21 crore (net of tax) relating to a final settlement from an insurance claim. The reported revenue stood at Rs 892 crore in Q1 FY26, up 10 per cent. The company's EBITDA (earnings before interest, taxes, depreciation, and amortisation) stood at Rs 224 crore—a 19 per cent increase—driven by revenue growth and cost optimisation. The EBITDA margin stood at 25 per cent. Bains added that Syngene continues to strengthen and expand its scientific platform capabilities, including the launch of a state-of-the-art, dedicated peptide laboratory, while remaining mindful of ongoing macroeconomic factors. Syngene has appointed Chethan Yogesh as the secretary and compliance officer of the company with effect from July 23. Yogesh was previously associated with technology firms including Wipro and IBM. The company also completed a USFDA GCP inspection of its Human Pharmacology Unit with no observations and received a favourable Voluntary Action Indicated (VAI) outcome for its Biologics facility. Syngene noted that over 20 client and regulatory audits in Q1 FY26 reinforced its global quality standards. Deepak Jain, chief financial officer, Syngene International Limited, said: 'The current quarter's PAT includes a tax benefit arising from transfer of gratuity funds to the Employee Gratuity Trust. We continue to maintain a robust balance sheet enabling us to invest in technology and capabilities to strengthen our customer offerings. While keeping a close watch on market trends, we remain on course to deliver in line with our stated guidance for the year.' Syngene announced its results after market close on Wednesday. During the session, the company's shares were up 0.50 per cent at Rs 679.65 apiece on the BSE.
